Shaalan Beg MD MBA FASCO
@ShaalanBeg
Followers
7K
Following
26K
Media
1K
Statuses
17K
Reimagining cancer clinical trials. Foodie, family guy, digital health. FCOI: https://t.co/CtEt9hUmRB
Dallas, Texas
Joined February 2015
The whole medical publishing ecosystem (free content, free peer review, but $$ to publish/read) is a bizarre, exploitative business model. Even if one believes clinicians owe some degree of unpaid "academic service," it’s absurd publishers profit so massively off our free labor.
In 2024, Elsevier publishers, parent company of @sciencedirect reported profits of over 3 Billion pounds and @SpringerNature reported over 1.8 billion pounds of profit. All off the work we do for them for free. Hey publishers, pay for reviews.
4
40
107
ctDNA may guide who benefits from extra therapy beyond standard chemo! @JAMAOnc @OncoAlert @isliquidbiopsy
https://t.co/zr8lpy3KNR
2
21
40
Announcing my 2026 Travel Awards! Goal is to help patients and trainees travel to any scientific conferences related to cancer. $500 each, very simple application, first round apps due 1/15. Go to @ACRORadOnc #ACRO2026, @ASCO #ASCO2026, or other. Deets at links 👇
2
11
46
Wow, many issues w this 47-pt, sponsor-run, single-arm histotripsy study. Short 🧵 1/4 1. Post-hoc imaging re-read: primary read w validated criteria showed 1-yr LC 63%, but they emphasize a post-hoc re-read (using new “experience” w histo imaging) bumping local control to 90%.
Hepatic histotripsy is a novel noninvasive ultrasound therapy for liver tumors, and 1-yr outcomes demonstrated that local tumor control and survival was consistent with other therapies.
4
28
68
This will help you understand why the big PBMs are bad. You can go to https://t.co/jkoJoin92G and buy a GLP1 for under $500 and falling. It's cheaper, because no PBM is involved Your company, uses a big PBM for your pharmacy benefits. It charges your company $1300 for a
130
625
4K
Futures Traders: Now you can get 30% off for life, never pay an activation fee, and get 100% initial test refunds with your first withdrawal! Use code NOFEE100 to claim this limited time offer.
0
11
62
@US_FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma! Durvalumab with FLOT is now approved in the perioperative setting for resectable gastric and GEJ cancer. A step forward. @OncoAlert @FDAOncology
0
9
23
⭐️Tissue-agnostic cancer therapies: promise, reality, and the path forward @NaturePortfolio
nature.com
Nature Communications - Tissue-agnostic cancer therapies promise to revolutionize oncology by targeting molecular drivers. Sledge et al.’s study of nearly 300,000 tumors found 21.5% with...
2
10
27
⭐️ESMO Basic Requirements for AI-based Biomarkers In Oncology (EBAI) - Annals of Oncology @Annals_Oncology @myESMO Fantastic work by @jnkath @mihaela_aldea @BenWestphalen The EBAI framework defines minimum requirements for AI-based biomarkers in oncology @OncoAlert
annalsofoncology.org
Artificial intelligence (AI) is expected to introduce an increasing number of biomarkers in oncology. To bridge the gap between oncology and computer science, it is timely to define recommendations...
1
13
26
Wow 1 day- 3 approvals for sevabertinib, starlatamab and selumetinib! Looks like FDA Onc wants a clean house by the Thanksgiving holidays!
0
14
42
The city was broke—but not broken. Drop Dead City, the 2025 documentary about NYC’s 1975 fiscal crisis, is out now. Don’t miss this smart, gripping and unexpectedly poignant story of urban survival, now streaming on all major platforms!
0
39
230
For patients with hepatocellular carcinoma, local therapy options are abundant yet challenging to prescribe. In a new editorial for #ASCODailyNews, @NiuSanford and @riadsalemIR offer a framework to guide local therapy decision-making in HCC: https://t.co/LglwHZRY2t
1
3
10
For patients with hepatocellular carcinoma, local therapy options are abundant yet challenging to prescribe. In a new editorial for #ASCODailyNews, @NiuSanford and @riadsalemIR offer a framework to guide local therapy decision-making in HCC: https://t.co/LglwHZRY2t
1
8
20
A New First-Line Standard for EGFR-Mutated NSCLC? First-line treatment of patients with EGFR-mutated NSCLC with osimertinib and platinum-pemetrexed chemotherapy leads to significantly longer overall survival than osimertinib alone. https://t.co/NZp6hjA9rk
#LungCancer @NEJM
1
2
7
Texans set to approve $3 billion dementia research fund
texastribune.org
The Dementia Prevention and Research Institute of Texas fund, a priority of Lt. Gov. Dan Patrick, will provide $3 billion in grants to researchers.
1
0
2
.@themuldermethod and I wanted kids to get a glimpse of what amazing things happen in #pathology and the #lab - we put it in story form. Order your copy of the (bestseller!) Mia the Marvelous Lab Explorer today! https://t.co/ULGzFQD2nj Join #MissionMarvelous
1
13
24
🏰 The Lord Marshal summons you on this first day of Christmas! Enter daily for a chance to win two tickets to the Castle. Ten champions will be chosen—could it be you? Click the link in our bio to enter!
4
11
143
@PanCAN @letswinpc @tacobell , my TacoBelle is rocking the purple harness for #PancreaticCancer during November, Pancreatic Cancer Awareness Month. @RealCapnCrunch @MrPeanut please help us spread the word and raise awareness for this deadly disease. Thanks
2
3
17
🔥off the press🔥 Clinical practice & implications of biomarker testing in biliary tract cancer: an observational study @JHEP_Reports
https://t.co/AGLiaNu63m 🔎RWD, 1500 pts, 18 centers 👉striking differences in GA detection rate 👉we provide predictive & prognostic impact of
3
30
89
Our framework for navigating local therapy options in HCC. With @riadsalemIR. Table below & details in #ASCODailyNews article. Recs take into account global practice patterns, tech availability, guidelines, etc. Always open to feedback🙂. https://t.co/nqjmhQ4nZR
@OncoAlert
2
28
67
Looking forward to speaking during the panel discussion at today’s First Nations celebration
0
1
3
My #HealthcareUnfiltered Podcast has turned SIX YEARS OLD. 6-YEARS. More than 250 episodes. More than 400 guests. THANK YOU from the bottom of my heart for listening, engaging & being part of the journey. Onward to more topics, more podcasts, more discussion, and more dialogue.
14
17
97
Powerhouse panel @ConquerCancerFd Retreat today to discuss emerging funding issues @teekayowo @ShaalanBeg @StoverLab and Lee Krug @AstraZeneca
1
3
20